Sublocade from Indivior - once-monthly injection reshapes US opioid treatment
Indivior's Sublocade, a once-monthly injection of buprenorphine, is transforming opioid use disorder treatment in the US by offering a stable, long-acting option for patients. This FDA-approved medication helps reduce daily decision-making for patients and is a strategic growth pillar for Indivior, supported by expanding insurance coverage and efforts to increase access. The article highlights its clinical benefits, safety considerations, and its importance to Indivior's business strategy and investor outlook.
Indivior PLC updates investors on business strategy. Focus on addiction treatment portfolio
Indivior PLC has updated investors on its long-term business strategy, emphasizing its leadership in addiction treatment, particularly for opioid use disorder. The strategy involves expanding its product portfolio, growing its global footprint, and investing in R&D, while also focusing on increasing access to its therapies. The company aims to balance established brands with new developments and manage regulatory requirements as it expands into new markets.
Indivior PLC outlines long-term strategy as addiction treatments remain in demand
Indivior PLC is focusing on expanding its portfolio of addiction treatments, particularly for opioid dependence, by investing in R&D for new formulations and delivery mechanisms. The company operates in a field influenced by evolving regulation and reimbursement policies, emphasizing the need to demonstrate clinical outcomes and cost-benefit data for its specialized medications. Indivior's long-term strategy aims to balance innovation with affordability to ensure continued access to therapy, with its stock performance closely tied to healthcare policies and treatment program trends.
Indivior stock holds the focus. US listing and product model frame the setup.
Indivior PLC maintains a clear US-market profile with its Nasdaq listing and focus on addiction treatment pharmaceuticals, specifically for opioid use disorder. The company's business model relies on specialty medicines like SUBLOCADE, driven by treatment access and prescription volume rather than pipeline developments. For US investors, the Nasdaq exposure keeps Indivior relevant within the domestic market conversation.
Indivior navigates addiction-treatment demand. Investors weigh long-term growth prospects
Indivior PLC, a specialty pharmaceutical company, operates at the intersection of addiction science and medicine, focusing on opioid-use disorder and related mental health conditions. The article examines how investors are evaluating its growth plans, product portfolio, and regulatory exposure. Key factors include the impact of regulation and competition, particularly in the US market, and the company's strategy of commercializing therapies through specialist prescribers and clinics.
Indivior consensus shapes expectations, shares on Nasdaq under analyst scrutiny
Indivior's Nasdaq listing is under analyst scrutiny, with a clear consensus forming around its earnings and valuation. This analysis focuses on how forecasts, ratings, and the sector context influence the risk-reward profile for retail investors. The company, known for its buprenorphine-based prescription drugs for opioid dependence, is covered by several international financial houses, primarily tracking its U.S. listing as Indivior Pharmaceuticals Inc. on Nasdaq.
Is Big Pharma's Patent Cliff Driving a New M&A Wave
The pharmaceutical industry is facing a significant "patent cliff" by 2032, driving a new wave of M&A activity as major pharma companies seek to acquire innovative assets to offset potential revenue losses. Indivior (INDV), specializing in buprenorphine-based addiction treatments, is highlighted as a compelling takeover target due to its niche market, strong financial performance, and strategic focus on its growth-driving product, Sublocade. Despite recent stock volatility and ongoing legal challenges, Indivior's robust earnings, cost-cutting measures, and share buyback program underscore its intrinsic value and potential for significant upside, making it an attractive prospect for strategic buyers.
Reasons Why Investors Should Consider Betting on Indivior Stock
Indivior (INDV) is positioned as a strong investment due to the commercial success of its Sublocade treatment for opioid use disorder, with management anticipating accelerated U.S. dispense-unit growth. The company also demonstrates disciplined capital allocation by focusing on high-value opportunities and implementing a cost-optimization program. Indivior currently holds a Zacks Rank #1 (Strong Buy) and its shares have outperformed the industry year-to-date.
Indivior stock reaches all-time high at 41.09 USD
Indivior PLC's stock has hit an all-time high of $41.09, reflecting a 197.82% increase over the past year and suggesting the shares are slightly undervalued according to InvestingPro analysis. This surge is attributed to strong financial performance, strategic initiatives, aggressive share buybacks, and positive first-quarter 2026 results which exceeded expectations. Barclays has initiated coverage with an overweight rating and a $46.00 price target.
Form 4 Indivior PLC For: 23 June By Investing.com
This article simply states that Form 4 for Indivior PLC for June 23 has been published by Investing.com. It provides no further details about the Form 4 itself, but includes various financial market data and popular news headlines as context on the publishing platform.
Form 4 Indivior PLC For: 23 June By Investing.com
This article is a Form 4 filing for Indivior PLC, indicating an insider trading report for June 23. It provides the title and date of the filing, along with a link to Investing.com. The content primarily consists of navigation menus, related articles, and market data rather than detailed information about the Form 4 itself.
Indivior Pharmaceuticals (INDV) CEO vests 1.27M shares, 612K for taxes
Indivior Pharmaceuticals' CEO, Joseph Ciaffoni, had 1,266,903 performance stock units vest on June 22, 2026, after 100% of performance conditions were met. To cover tax withholding obligations, 612,549 of these shares were withheld, resulting in Ciaffoni directly holding 790,330 shares of common stock. This transaction is reflected in a Form 4 filing, indicating an exercise/conversion of derivative securities and a tax withholding disposition.
Indivior - Weekly outlook on earnings and strategy
This article provides an outlook on Indivior's upcoming week, highlighting the absence of new market-moving headlines and focusing investor attention on the earnings calendar, legal settlements, and strategy in opioid use disorder treatments. It details how the company generates revenue and where its stock trades, while emphasizing the lack of specific price data. The piece also notes that the article was AI-assisted and editorially reviewed, with disclaimers regarding data accuracy and investment advice.
Indivior Stock - Sunday background on the addiction-treatment specialist
This article provides a Sunday background on Indivior, a UK-based addiction-treatment specialist, focusing on its corporate history, product portfolio, and regulatory landscape. Since there's no fresh weekend news, it offers retail investors a structured overview of the company's business model, management, financial profile, and risks and opportunities within the highly regulated addiction treatment market. The article highlights Indivior's focus on opioid-use disorder therapies and its position relative to larger pharmaceutical companies, emphasizing the importance of its regulatory and legal backdrop.
Indivior PLC (INDV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Indivior PLC (INDV), focusing on its regional contributions. As of the specified data, the United States accounts for 85.03% of the company's revenue, totaling $267.00 million, while the Rest of World contributes 14.97% or $47.00 million. Data for business segments and detailed quarterly financial years beyond what's indicated as "not disclosed" is not yet available.
Why Indivior’s Once?Monthly Sublocade shot is changing opioid treatment routines
Indivior's Sublocade is a once-monthly, extended-release buprenorphine injection designed to treat opioid use disorder, offering an alternative to daily pills. This treatment aims to provide stable buprenorphine levels, reducing daily dosing burden and diversion risk, though it raises questions about access and potential injection-site reactions. Sublocade is a key product for Indivior, especially in North America, highlighting a shift towards long-acting therapies in addiction treatment.
Indivior PLC (INDV) Valuation: PE, PB & Fair Value Analysis
Indivior PLC (INDV) currently has a valuation score of 9.73, ranking 7th out of 157 companies in the Pharmaceuticals industry. Its P/E ratio stands at 22.80, which is significantly below its recent high and above its recent low. However, relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Barclays Initiates Indivior at Overweight With $46 Price Target
Barclays has initiated coverage on Indivior with an "Overweight" rating and a price target of $46. This follows recent news including insider share sales, positive findings from real-world evidence studies, and the company's financial performance. Indivior Pharmaceuticals is a global company focused on developing medicines for substance-use disorders, with core products like SUBLOCADE and SUBOXONE for opioid use disorder.
Indivior PLC (INDV) Institutional Confidence
Indivior PLC (INDV) has an institutional shareholding score of 10.00, placing it first in the Pharmaceuticals industry. The institutional shareholding proportion increased by 64,038,000% quarter-over-quarter, reaching 102.46%. Bill Nygren (OAKMX) is the largest institutional shareholder, holding 140.93K shares, a 1300% increase in holdings.
Indivior PLC (INDV) Financial Health: Profitability & Balance Sheet Analysis
Indivior PLC (INDV) has a current financial score of 7.94, placing it 92nd out of 157 in the Pharmaceuticals industry, indicating a weak financial status but high operating efficiency. The company recently reported a 19.17% year-over-year increase in quarterly revenue to $317.00M and a 93.48% increase in net profit. While its financial health rating is low, its operational efficiency and growth potential scores are high, each at 10.00.
Indivior PLC (INDV) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Indivior PLC (INDV), focusing on its price momentum, support and resistance levels, and various technical indicators like MACD, RSI, and moving averages. The stock currently has a price momentum score of 9.24 and is trading between a resistance level of 40.50 and a support level of 33.97. Based on the aggregated signals, the overall recommendation is to Buy.
Indivior PLC Stock (GB00BYZ0C031): Tuesday focus on positioning after recent volatility
Indivior PLC stock is drawing attention on Tuesday due to its positioning in algorithmic trading frameworks and small-cap portfolios, rather than new company-specific news. Despite a quiet news day, the stock's recent price behavior, inclusion in ETFs like the Federated Hermes MDT Small Cap Core ETF, and a track record of surpassing earnings expectations are influencing trading dynamics. The company, specializing in opioid use disorder treatments like Sublocade, remains a focus for both systematic and fundamentally oriented investors.
Indivior PLC (INDV) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Indivior PLC (INDV), noting its current risk score of 6.43, which ranks 54 out of 159 in the Pharmaceuticals industry. The company has a beta of 1.18, indicating higher volatility compared to the S&P 500. The report details various volatility, return, drawdown, and liquidity metrics over different timeframes for INDV.
Indivior's Chief Scientific Officer Sold Over 18,000 Company Shares. Should Investors Worry?
Indivior's Chief Scientific Officer, Christian Heidbreder, sold 18,586 shares for $707,383, which represented 7.54% of his direct holdings. This transaction was part of a pre-arranged Rule 10b5-1 trading plan and occurred after the company's stock soared 177% over the past year due to strong financial performance, including significant increases in Q1 revenue and net income. Investors should not be concerned as the sale was planned and the company's fundamentals remain strong.
Indivior PLC (INDV) Earnings Forecast: Future EPS & Revenue Growth Estimates
Indivior PLC (INDV) has an earnings forecast score of 8.67, ranking 13th in the Pharmaceuticals industry, with an average analyst price target of $36.00 and expectations for future revenue and EPS growth. Analysts widely recommend a "Buy" for INDV stock, anticipating an upside space of nearly 30%. The company's EPS for the previous quarter surpassed market expectations, and further growth is projected for the next quarter.
Is Indivior Pharmaceuticals, Inc. (INDV) A Good Stock To Buy Now?
This article analyzes whether Indivior Pharmaceuticals, Inc. (INDV) is a good investment, summarizing a bullish thesis from The Mispricing Desk. Indivior's SUBLOCADE franchise is driving strong growth and cash generation, leading to raised full-year guidance and significant share repurchases. Despite past pipeline disappointments, the company is seen as undervalued due to improving profitability and a focus on shareholder value creation through disciplined capital allocation.
Indivior PLC Stock (GB00BYZ0C031): US-listed opioid-addiction specialist stays in focus after Q1 upd
Indivior PLC, a US-listed opioid-addiction treatment specialist, remains a focal point for investors following its latest quarterly update. The company's performance is heavily tied to its opioid-use-disorder portfolio, particularly long-acting injectable formulations, and continues to be influenced by ongoing litigation risks and the evolving policy environment surrounding addiction treatments in the US. Investors are closely scrutinizing revenue growth, legal accruals, and the impact of policy and clinical practice trends on the company's financial flexibility.
Is Indivior Stock a Buy After Higher 2026 Guidance?
Indivior (INDV) reported strong Q1 2026 results with earnings and revenue beating estimates, driven by demand for its Sublocade product. The company raised its full-year 2026 guidance for net revenues and adjusted EBITDA, indicating improved profitability through cost actions and balance sheet management. Indivior's stock has performed well, and its valuation is discussed in the context of its higher guidance and capital allocation strategies.
INDV Stock: What Sublocade Growth Signals for 2026
Indivior Pharmaceuticals (INDV) is increasingly relying on Sublocade, its buprenorphine therapy, to drive revenue growth, with strong first-quarter 2026 results showing a 32% increase in Sublocade net revenues. The company's 2026 outlook projects Sublocade sales of $950-$990 million, driven by continued commercial execution and marketing investment. Despite its strong market position and growth prospects, INDV faces risks related to product concentration, pipeline uncertainty, and ongoing legal exposure.
INDV and the Shift to Long-Acting Opioid Use Disorder Care in 2026
Indivior (INDV) is poised for significant growth in 2026 due to a market shift towards long-acting injectable treatments for opioid use disorder, a segment with low penetration but high potential. The company's enhanced commercial strategies and consumer campaigns are expected to boost its Sublocade product, maintaining its strong market share and payer access. Despite pipeline setbacks, Indivior is focusing on external business development and sustaining patient growth, with a "Strong Buy" Zacks Rank.
Is Indivior Stock a Buy After Higher 2026 Guidance?
Indivior Pharmaceuticals (INDV) has revised its 2026 guidance upward following a strong first quarter, primarily driven by the performance of its opioid use disorder treatment, Sublocade. The company's strategy now focuses on profitability, expense discipline, and capital allocation, including share repurchases. While Indivior's stock has seen significant gains, investors are advised to monitor Sublocade's sustained growth and margin durability to assess future performance.
Indivior CFO Ryan Preblick sells $1.36m in company stock
Indivior CFO Ryan Preblick sold 36,000 shares of company stock worth $1.36 million on June 8, 2026, through a pre-arranged trading plan. Despite Indivior's stock surging nearly 180% over the past year, analysis suggests it remains undervalued. The sale follows strong Q1 2026 financial results and a $175 million share repurchase agreement.
Indivior PLC stock (GB00BYZ0C031): focus on addiction treatments amid US legal overhang
Indivior PLC specializes in addiction treatments, particularly for opioid use disorder, with a strong focus on the U.S. market. The company’s business model involves developing buprenorphine-based therapies and investing in R&D to expand its pipeline beyond legacy products like Suboxone. Despite being a key player in addressing the opioid crisis, Indivior faces ongoing legal and patent risks, competitive pressures, and sensitivity to US healthcare policy changes, which significantly impact its stock valuation and long-term prospects.
Indivior PLC stock (US45580R1068): Opioid-treatment specialist in focus after Q1 update and ongoing
Indivior PLC is drawing attention after its Q1 2026 results and plans for a US primary listing, driven by its focus on opioid-use-disorder treatments, particularly its strong-performing Sublocade. The company aims to align its listing with its predominant US revenue and investor base, while navigating ongoing legal settlements and competitive pressures on older products. This strategy positions Indivior as a targeted investment in the US addiction-treatment market, with future valuation tied to regulatory and commercial developments.
Indivior PLC stock (US45580R1068): valuation metrics in focus after steady Nasdaq trading
Indivior PLC's stock (INDV) on Nasdaq traded steadily around USD 15.45 as of June 5, 2026, drawing investor attention to its valuation metrics. The UK-based addiction-treatment specialist's valuation is being assessed in light of its latest earnings and ongoing legal settlements related to opioids. Investors are focusing on metrics like P/E ratio and enterprise-value-to-EBITDA to gauge its market position compared to other specialty pharmaceutical companies.
Zacks.com featured highlights include Indivior, ReNew Energy, Lifetime, NetScout and TEEKAY
This Zacks.com article highlights five top-ranked efficient stocks: Indivior, ReNew Energy, Lifetime Brands, NetScout Systems, and TEEKAY TANK LTD. These companies were selected based on key efficiency metrics like receivables turnover, asset utilization, inventory turnover, and operating margin. The article details how these metrics indicate a company's profit-generating potential and strong price performance, showcasing the impressive earnings surprise of each selected firm.
Indivior PLC stock (GB00BYZ0C031): U.S.-listed shares trade steadily as investors watch litigation a
Indivior PLC's U.S.-listed shares are trading steadily on Nasdaq as investors weigh ongoing litigation against the company's strong growth in addiction treatment products and broader sector sentiment. The company, which specializes in opioid-use disorder treatments, has consistently beaten earnings estimates, yet faces a class-action lawsuit. Analysts have set an average 12-month target price of around USD 19 for its American Depositary Shares.
Zacks.com featured highlights include Indivior, ReNew Energy, Lifetime, NetScout and TEEKAY
Zacks.com has identified five top-ranked efficient stocks that are outperforming their industry peers based on key metrics. The featured companies are Indivior Pharmaceuticals (INDV), ReNew Energy Global (RNW), Lifetime Brands (LCUT), NetScout Systems (NTCT), and TEEKAY TANK LTD (TNK). These selections are based on efficiency ratios such as Receivables Turnover, Asset Utilization, Inventory Turnover, and Operating Margin, indicating strong profit-generating potential.
INDV - Indivior Pharmaceuticals Inc Stock Price and Quote
This article provides a detailed stock quote and financial overview for Indivior Pharmaceuticals Inc. (INDV), including its latest stock price, financial metrics, analyst ratings, and recent news. It highlights the company's focus on opioid use disorder treatment and includes insider trading activity.
What to Know About This Fund's $74.8 Million Indivior Sale
Divisadero Street Capital Management sold 2,263,703 shares of Indivior for an estimated $74.76 million in the first quarter of 2026, representing a significant reduction in their position. This sale is seen as profit-taking after Indivior's stock performance and strong first-quarter revenue growth, with the company raising its 2026 guidance. The ARTICLE highlights Indivior's financial metrics and its role in the opioid addiction treatment market, asking if its growth can sustain its stock's run.
What to Know About This Fund's $74.8 Million Indivior Sale
Divisadero Street Capital Management sold 2,263,703 shares of Indivior for an estimated $74.76 million in the first quarter of 2026, a move seen as profit-taking after the stock's significant run-up. Despite the sale, Indivior's business momentum remains strong, with first-quarter revenue rising 19% and adjusted EBITDA more than doubling, leading to an increased 2026 guidance. Investors are now questioning if the company's growth can continue to justify its massive stock performance.
What to Know About This Fund's $74.8 Million Indivior Sale
Divisadero Street Capital Management recently sold 2,263,703 shares of Indivior for an estimated $74.76 million, reducing its stake in the company. Despite the sale, Indivior, which develops buprenorphine-based opioid dependence treatments, has shown strong performance with a 19% increase in Q1 revenue and a significant rise in adjusted EBITDA. The transaction appears to be profit-taking after Indivior's stock surged nearly 200% over the past year, with the company's underlying business momentum remaining robust and management raising its 2026 guidance.
Indivior PLC stock (GB00BYZ0C031): valuation metrics in focus as London-listed shares consolidate after recent volatility
Indivior PLC shares traded in a tight range on the London Stock Exchange as investors reassessed the company's valuation following its latest quarterly figures and ongoing U.S. legal matters concerning opioid treatments. The company reported solid revenue growth driven by its Sublocade treatment but continues to manage legal issues related to historical marketing practices, which contribute to earnings uncertainty. Market participants are closely watching for updates on forward guidance and legal developments to gauge the stock's future performance.
Indivior PLC stock (GB00BYZ0C031): focus on addiction treatments after strong 2024 earnings
Indivior PLC, a specialty pharmaceutical group, is sharpening its focus on opioid use disorder and addiction therapies, supported by robust 2024 earnings. The company is actively pursuing a primary US listing to enhance its access to American capital markets and emphasizes long-acting injectable treatments as key strategic priorities. Indivior's business model centers on evidence-based pharmacotherapies and strong engagement with policymakers and payers to address substance use disorders, primarily within the US market.
Indivior PLC stock (GB00BYZ0C031): opioid-dependence specialist in the spotlight after latest earnings
Indivior PLC (GB00BYZ0C031) is attracting investor attention due to its recent quarterly performance, particularly its opioid-dependence portfolio led by Sublocade, and ongoing litigation. The specialty pharmaceutical company is focused on transitioning from older formulations to long-acting injectables like Sublocade to drive growth and manage generic competition. Its success is closely tied to US healthcare policy, reimbursement decisions, and its ability to navigate legal and competitive pressures within the addiction treatment market.
Indivior PLC stock (GB00BYZ0C031): Opioid-treatment specialist faces DOJ settlement while preparing US relisting
Indivior PLC has reached an agreement in principle with the US Department of Justice to settle civil claims regarding past marketing practices for its opioid-dependence treatment, Suboxone. Simultaneously, the company is preparing to shift its primary stock listing from London to the United States to better reflect its revenue focus on the US market. These developments aim to resolve legal uncertainties and enhance investor access, particularly for American investors.
Indivior PLC stock (GB00BYZ0C031): Q1 revenue rises on Sublocade momentum
Indivior PLC reported strong double-digit revenue growth in Q1 2026, primarily driven by the continued increase in sales of its opioid use disorder treatment, Sublocade. The company generated approximately $317 million in net revenue, marking a 19% year-over-year increase, and remains focused on expanding its addiction treatment portfolio in North America. Indivior's strategy emphasizes evidence-based therapies like Sublocade, supported by clinical data demonstrating its effectiveness in reducing relapse.
New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization
Two new real-world evidence studies by Indivior Pharmaceuticals Inc. show that adherence to monthly injectable buprenorphine (SUBLOCADE®) significantly reduces the risk of opioid use disorder relapse and lowers healthcare utilization. Patients on this treatment were 3.5 to 8.1 times less likely to return to opioid use and experienced fewer infection-related complications and acute care visits compared to those on other buprenorphine treatments. The findings highlight the importance of sustained treatment in improving outcomes for OUD patients.
Indivior PLC stock (GB00BYZ0C031): opioid-treatment specialist under pressure after US listing plan
Indivior PLC, a specialist in opioid use disorder medications with a primary sales market in the US, is planning a Nasdaq listing while navigating ongoing legal challenges and competitive pressures. The company aims to align its market profile with its US revenue base and broaden access to US healthcare-focused investors. This strategic shift and the company's efforts to grow newer formulations and manage litigation are key factors for investors evaluating the stock.
Indivior PLC stock (GB00BYZ0C031): FDA setback for opioid use disorder injection puts focus on pipel
Indivior PLC faced an FDA Complete Response Letter for its RBP-6000 injectable buprenorphine product, raising concerns about its US growth strategy and competitive landscape in opioid use disorder treatments. This setback highlights the company's reliance on its long-acting injectable pipeline and the evolving regulatory environment for addiction therapies. Despite the challenge, the article emphasizes the continued relevance of Indivior's focus due to the ongoing US opioid crisis and policy efforts to expand treatment access.
